Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Clinical Development
Biologics
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending T
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Clinical Development
Biologics
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
elafibranor
Biotech
Ipsen posts mixed liver disease data on Intercept, CymaBay rival
The phase 3 trial publication provides a closer look at how the liver therapy holds up against Intercept’s Ocaliva and CymaBay’s own challenger.
Nick Paul Taylor
Nov 14, 2023 5:55am
Ipsen, Genfit report phase 3 rare liver disease success
Jun 30, 2023 6:15am
Genfit cans phase 3 NASH trial after failing interim analysis
Jul 23, 2020 7:20am
Genfit's NASH prospect flops in phase 3
May 11, 2020 7:13pm
COVID-19 unlikely to 'significantly delay' Genfit's NASH data
Mar 31, 2020 8:43am
